Urinary Biomarkers Can Predict Response in Lupus Nephritis

This article originally appeared here.
Share this content:
Urinary Biomarkers Can Predict Response in Lupus Nephritis
Urinary Biomarkers Can Predict Response in Lupus Nephritis

TUESDAY, Aug. 2, 2016 (HealthDay News) -- Low abundance biomarker panels can predict lupus nephritis outcomes, according to research published online July 27 in Arthritis & Rheumatology.

Noting that the American College of Rheumatology guidelines recommend change in lupus nephritis induction therapy when no response has occurred within six months, Bethany J. Wolf, Ph.D., from the University of South Carolina in Charleston, and colleagues analyzed biomarker models to develop a tool for defining response. In 140 patients with biopsy-proven lupus nephritis who had not yet started induction therapy, the authors analyzed urine samples for a panel of urinary biomarkers. For each individual biomarker, they generated univariate receiver operating characteristic (ROC) curves, and compared them to the ROC area under the curve values from models developed using random forest algorithms.

The researchers found that there was clinically meaningful predictive power for models developed with the combined traditional and novel biomarker panels. Chemokines, cytokines, and markers of cellular damage were the most predictive of response.

"This is the first study to demonstrate the power of low-abundance biomarker panels and machine learning algorithms for predicting lupus nephritis outcomes," the authors write. "This is a critical first step in research to develop clinically meaningful decision support tools."

Subject materials were provided by Genentech and Bristol-Myers Squibb.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Illicit Marijuana Use Up in States With Legal Medical Use

Illicit Marijuana Use Up in States With Legal ...

Cannabis use disorder is also rising faster in states with legalization laws

Chromosome Instability Test Prognostic in NSCLC

Chromosome Instability Test Prognostic in NSCLC

Chromosome instability associated with higher risk of relapse, death within 2 years

CDC: Opioid-Related Mortality Rate Might Be Underestimated

CDC: Opioid-Related Mortality Rate Might Be Underestimated

Death certificates from drug-linked infections may not label opioids as possible cause

is free, fast, and customized just for you!

Already a member?

Sign In Now »